Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab. (2021)

• Record Type: Journal Article
• Authors: Kojima, Yuichi; Takeyabu, Kimihiro; Kimura, Mizuki; Matunaga, Akihiro; Kudou, Jyunya; Ohata, Yoshihiro; Satoh, Miki; Tobioka, Hirotoshi; Ishikawa, Keidai; Kawamura, Takeshi
• Is Part Of: Respiratory medicine case reports. Volume 34(2021)
• Publication Date: 2021
• Subjects: Pulmonary pleomorphic carcinoma -- S-1 -- Pembrolizumab -- Second line treatment -- Programmed cell death ligand 1 -- Tegafur; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2021.101501
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: The patient was an 80-year-old woman with combined pulmonary fibrosis and emphysema. She was diagnosed with pulmonary pleomorphic carcinoma in the right upper lobe, which relapsed 18 months after the operation. Computed tomography showed a mass in contact with the posterior wall of the lower part of the stomach. The patient was treated with two cycles of pembrolizumab, but the disease progressed. She was treated with S-1 as second-line therapy, resulting in tumor-shrinking after two cycles. Progression was not observed over the next twelve months. We report a rare case involving S-1 after immune checkpoint inhibitor treatment.